Fluidigm Corporation (NASDAQ:FLDM) Q4 2019 Earnings Conference Call - Final Transcript
Feb 10, 2020 • 05:00 pm ET
Good afternoon, ladies and gentlemen, and welcome to the Fluidigm Fourth Quarter 2019 Financial Results Conference Call. [Operator Instructions] As a reminder, this conference call is being recorded.
I would now like to turn the conference over to your host, Ms. Agnes Lee, Vice President, Investor Relations. Please go ahead, ma'am.
Thank you. Good afternoon, everyone. Welcome to the Fluidigm fourth quarter 2019 earnings conference call. At the close of the market today, Fluidigm released its financial results for the quarter and full year ended December 31, 2019. During this call, we will review our results and provide commentary on recent commercial activity, market trends and our strategic business initiative. Presenting for Fluidigm today will be Chris Linthwaite, our President and Chief Executive Officer and Vikram Jog, our Chief Financial Officer.
During the call and subsequent Q&A session, we will make forward-looking statements about events and circumstances that have not yet occurred, including plans and projections for our future business -- future financial results and market trends and opportunities. Examples include statements about expected revenue growth, the anticipated positive impact of various strategic and operational initiatives, prospects for our products and
Technologies, potential customers and collaborators, trends in competition, markets, research funding and customer demand and guidance for revenues and operating loss for the full year 2020. These statements are subject to substantial risks and uncertainties that may cause actual events or results to differ materially from current expectations. Information on these risks and uncertainties and other information affecting our business and operating results is contained in our annual report on Form 10-K for the year ended December 31, 2018, as well as our other filings with the SEC. The forward-looking statements in this call are based on information currently available to us and Fluidigm disclaims any obligation to update these forward-looking statements, except as may be required by law.
During the call, we will also present some financial information on a non-GAAP basis. Non-GAAP information is not prepared under a comprehensive set of accounting rules and should only be used to supplement an understanding of the Company's operating results as reported under U.S. GAAP. We encourage you to carefully consider our results under GAAP as well as our supplemental non-GAAP information and the reconciliation between these presentations. Reconciliations between GAAP and non-GAAP operating results are presented in the table accompanying our earnings release, which can be found in the Investors section of our website.
I will now turn the call over to Chris, our President and CEO.
Thank you, Agnes. Good afternoon. Thank you for joining our fourth quarter and full year 2019 earnings call. The discovery and deployment of new biomarkers for disease insight and treatment is becoming more and more important to our industry, particularly biomarkers related to the immune system. We think this will be one of the biggest trends in life science research in the coming decade. As new biomarkers are revealed, integrating them into clinical study requires technologies that allow many simultaneous measurements. Fluidigm is